Stock analysts at StockNews.com started coverage on shares of Aptevo Therapeutics (NASDAQ:APVO – Get Free Report) in a note issued to investors on Tuesday. The brokerage set a “sell” rating on the biotechnology company’s stock.
Aptevo Therapeutics Trading Up 2.7 %
Shares of APVO opened at $0.36 on Tuesday. The stock has a 50 day moving average price of $0.38 and a 200 day moving average price of $1.80. Aptevo Therapeutics has a one year low of $0.28 and a one year high of $21.56.
Aptevo Therapeutics (NASDAQ:APVO – Get Free Report) last released its earnings results on Thursday, August 8th. The biotechnology company reported ($1.67) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.93) by $0.26. Equities analysts anticipate that Aptevo Therapeutics will post -4.3 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Aptevo Therapeutics Company Profile
Aptevo Therapeutics Inc, a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.
Read More
- Five stocks we like better than Aptevo Therapeutics
- How Can Investors Benefit From After-Hours Trading
- Why Dick’s Could Be a Slam Dunk for Your Investment Portfolio
- Basic Materials Stocks Investing
- Introduction to Fibonacci Retracement Levels
- What is Forex and How Does it Work?
- Top 3 Stocks to Outperform the S&P 500 in a Downturn
Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.